APA

Thatcher N., Hirsch F. R., Luft A. V., Szczesna A., Ciuleanu T. E., Dediu M., Ramlau R., Galiulin R. K., Bálint B., Losonczy G., Kazarnowicz A., Park K., Schumann C., Reck M., Depenbrock H., Nanda S., Kruljac-Letunic A., Kurek R., Paz-Ares L. & Socinski M. A. (20150928). Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. : The Lancet. Oncology.

Chicago

Thatcher Nick, Hirsch Fred R, Luft Alexander V, Szczesna Aleksandra, Ciuleanu Tudor E, Dediu Mircea, Ramlau Rodryg, Galiulin Rinat K, Bálint Beatrix, Losonczy György, Kazarnowicz Andrzej, Park Keunchil, Schumann Christian, Reck Martin, Depenbrock Henrik, Nanda Shivani, Kruljac-Letunic Anamarija, Kurek Raffael, Paz-Ares Luis and Socinski Mark A. 20150928. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. : The Lancet. Oncology.

Harvard

Thatcher N., Hirsch F. R., Luft A. V., Szczesna A., Ciuleanu T. E., Dediu M., Ramlau R., Galiulin R. K., Bálint B., Losonczy G., Kazarnowicz A., Park K., Schumann C., Reck M., Depenbrock H., Nanda S., Kruljac-Letunic A., Kurek R., Paz-Ares L. and Socinski M. A. (20150928). Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. : The Lancet. Oncology.

MLA

Thatcher Nick, Hirsch Fred R, Luft Alexander V, Szczesna Aleksandra, Ciuleanu Tudor E, Dediu Mircea, Ramlau Rodryg, Galiulin Rinat K, Bálint Beatrix, Losonczy György, Kazarnowicz Andrzej, Park Keunchil, Schumann Christian, Reck Martin, Depenbrock Henrik, Nanda Shivani, Kruljac-Letunic Anamarija, Kurek Raffael, Paz-Ares Luis and Socinski Mark A. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. : The Lancet. Oncology. 20150928.